Team uses antibodies to tag disease-related proteins for destruction
Researchers have developed a technique utilising antibodies to tag disease-causing proteins, to treat the underlying causes of disease.
List view / Grid view
Researchers have developed a technique utilising antibodies to tag disease-causing proteins, to treat the underlying causes of disease.
Researchers have developed a CAR T-cell engineering technique to ensure that only cancer cells are targeted, leaving healthy cells alone in solid tumours.
Researchers have developed a cell-based assay for the discovery of new IDO1 inhibitors, overcoming challenges from cell-free assays.
A large number of nanorobots in the bladders of mice have been visualised to reveal their movement and behaviour.
A team has revealed a function of ADAR1, responsible for RNA editing, discovering an isoform used for cancer growth, making it a drug target.
Researchers have produced the first 3D image of the Mediator-bound pre-initiation complex, key in the regulation of gene expression.
A team has developed a novel inhibitor that blocks a protein in cancer cells, making drug-resistant tumours respond to chemotherapy.
Researches have provided a proof-of-concept that proteomic analysis could be used to identify drivers of aggressive cancers.
A team has discovered how enzymes control the formation of bioactive rubromycin-polyketides, which could be used to bioengineer new compounds.
A team has used two viruses to administer specific tumour components in mice with cancer to stimulate their immune system.
Researchers have developed a new technique called mim-tRNAseq to measure, map and analyse tRNAs in cells, providing insight into disease.
Researchers have shown that inhibiting Treg activation in tumours can provide effective immune responses without autoimmune toxicity.
A high-throughput screening assay for macrocyclic peptides with affinity to ubiquitin has been created by researchers.
Research has shown that MAPK4 activates two molecules in cellular signalling pathways involved in prostate cancer growth.
A proton therapy that targets cancer cells which are resistant to treatment has shown success, sparing surrounding healthy cells.